OSR Health (OSRH) Non Operating Interest Expenses (2024 - 2026)
OSR Health's (OSRH) quarterly Non Operating Interest Expenses came in at $199024.0 in Q2 2026, down 3.83% year-over-year from $206960.0 in Q2 2025, and down 18.19% quarter-over-quarter from $243289.2 in Q1 2026.
Analysis
OSR Health (OSRH) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends
OSR Health has disclosed Non Operating Interest Expenses across 3 years of filings, most recently posting $199024.0 for Q2 2026.
- In Q2 2026, Non Operating Interest Expenses fell 3.83% year-over-year to $199024.0; the TTM figure through Jun 2026 stood at $6.2 million (down 29.56% YoY), while the FY2025 annual figure was $14.4 million, up 5257.59% from the prior year.
- Non Operating Interest Expenses came in at $199024.0 for Q2 2026 at OSR Health, down from $243289.2 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $8.5 million in Q1 2025 to a low of $9114.0 in Q3 2024.
- Average Non Operating Interest Expenses over 3 years is $1.5 million, with a median of $202992.0 recorded in 2025.
- Year-over-year, Non Operating Interest Expenses soared 11758.2% in 2025 and slumped 97.13% in 2026.
- Over 3 years, Non Operating Interest Expenses stood at $163566.0 in 2024, then jumped by 3029.89% to $5.1 million in 2025, then slumped by 96.11% to $199024.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $199024.0 in Q2 2026, $243289.2 in Q1 2026, and $5.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | OSR Health | 6.59 Mn | 4.94 Mn | 86,605.00 | 199,024.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 199,024.00 |
| Mar 31, 2026 | 243,289.19 |
| Dec 31, 2025 | 5.12 Mn |
| Sep 30, 2025 | 685,218.00 |
| Jun 30, 2025 | 206,960.00 |
| Mar 31, 2025 | 8.49 Mn |
| Dec 31, 2024 | 163,566.00 |
| Sep 30, 2024 | 9,114.00 |
| Jun 30, 2024 | 69,358.00 |
| Mar 31, 2024 | 71,591.00 |